Selentus Science is pleased to announce that its patent for TenaTac®, an innovative, adhesive surgical haemostat, has been allowed for grant in the UK, following an earlier grant in the USA. TenaTac is a Class III CE marked medical device that was approved for human surgical use in late 2019. TenaTac is now also available to veterinary surgeons in the UK; for further information please visit www.Selentus.com

This article was written by Medilink EM Member, Selentus Science.

For more information on Medilink Membership, click here

Latest Opportunities

Single manufacturer & supplier required for human skin patch: Formulation, manufacture, and packing

Opportunity Company:  Nottingham-based MedTech company Requires: Seeking a single manufacturer and supplier for the formulation,…

Medilink Midlands Job Vacancy - Innovation Adviser

About the job Innovation Adviser – Midlands region – Full time salary £40-45K – Home…

Global Business Innovation Programme: Health & Medical Technologies - Singapore

Innovate UK is inviting ambitious innovative companies to participate in its Global Business Innovation Programme…

Latest News

Cambridge Sleep Sciences Unveils World-First Performance Pillow That Adapts to Users’ Sleep

Cambridge Sleep Sciences Unveils World-First Performance Pillow That Adapts to Users’ Sleep – Helping Gamers…

Kindeva Opens New UK HQ and Manufacturing Site for the Development of Next-Generation Propellants

Kindeva, a global CDMO and drug delivery expert, has officially opened its new UK headquarters…

EU MDR/IVDR Revision: A Gateway for Chinese Innovators Entering UK and EU Markets via EFEC

In a significant move for the global medtech landscape, the European Commission has initiated a…